Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application

Ya, Zhao; Yan, Zhipeng; Liu, Ying; Zhang, Yue; Shi, Jihong; Li, Jingtao; Ji, Fanpu

doi:10.1186/s13287-021-02551-y

Cited by 27 publications

(22 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials have shown that intravenous MSCs are effective and safe for treating patients with severe IPF, improving lung function and fibrosis scores under CT, and increasing the 6-min walk distance. The most common source of MSCs in clinical trials of MSCs as IPF treatment is the bone marrow [ 15 ]. After transplantation, BMSCs can migrate to damaged lung tissues, modulate immune cell function, reduce local inflammation, and inhibit fibrosis through various pathways such as paracrine secretion.…”

Section: Discussionmentioning

confidence: 99%

“…Mesenchymal stem cell (MSC) transplantation is a new approach to treating PF [ 14 ]. These cells can reduce the inflammatory response, promote epithelial repair, and reduce the deposition of pulmonary extracellular matrix in PF lung tissues through multidirectional differentiation, immune regulation, and paracrine functions [ 15 ]. Astragalus and its metabolites can promote the proliferation, differentiation, and migration of MSCs [ 16 – 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Effect of Astragali Radix Extract Injection Combined with Bone Marrow Mesenchymal Stem Cells in Bleomycin-Induced Pulmonary Fibrotic Rats

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Pulmonary fibrosis is a serious disease for which effective drugs are unavailable. Here, we treated rat models of bleomycin (BLM)-induced pulmonary fibrosis with Astragali Radix extract injection (AI) combined with or without bone marrow mesenchymal stem cells (BMSCs). We injected rats intratracheally with BLM and transplanted BMSCs via tail vein injection 15 days later. We also intraperitoneally injected AI daily from days 15 to 28. Changes in lung pathology and function, as well as the levels of matrix metalloproteinases, collagen, C-X-C motif chemokine ligand 12 (CXCL12), and cluster of differentiation 90 (CD90) were assessed. The results revealed that compared with the BLM group, groups treated with ARE and BMSCs (alone or combined) reduced the expression levels of TGF-β1 and collagens I and III, ameliorated pathological lung fibrotic damage, and improved lung function. The expression levels of MMP-1, MMP-3, and MMP-9 were reduced by either AI or BMSCs alone, whereas those of MMP-3, MMP-9, TIMP-1, CXCL12, and CD90 were elevated by combined AI and BMSCs compared with the BLM group. Overall, these findings demonstrated that AI and BMSCs both can reduce damage caused by PF in rats and that AI altered the expression of chemokines and surface markers in BMSCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Therapeutic Effect of Astragali Radix Extract Injection Combined with Bone Marrow Mesenchymal Stem Cells in Bleomycin-Induced Pulmonary Fibrotic Rats

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…SASP factors can lead to abnormal wound healing, characterized by abnormal crosstalk between epithelial and mesenchymal cells, and the subsequent accumulation of myofibroblasts [6]. It has been observed that fibroblasts and myofibroblasts in fibrotic lungs show signs of stress and senescence, including resistance to apoptosis and excessive production of extracellular matrix components [13]. Moreover, fibrosis could result from this increase in matrix stiffness, which leads to irreversible tissue damage [14].…”

Section: Introductionmentioning

confidence: 99%

“…Collectively stating that fibrosis of the lungs is a chronic, progressive, fibrotic interstitial disease with a poor prognosis [15]. Currently, it has no effective treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, it has no effective treatment. Based on previous coronavirus infections, such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), as well as current clinical evidence from Coronavi-rus disease 2019, SARS-CoV-2 infection is likely to cause PF, which has a negative impact on patient prognosis and quality of life [15]. Hence, PF prevention and treatment can not only aid in improving the overall well-being of patient's outcomes after SARS-COV-2 but also reduce overall social and economic burdens.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Untitled

2022

IJCMCR

View full text Add to dashboard Cite

Initially, SARS-CoV-2 caused viral pneumonia; however, subsequent experience has shown that it manifests throughout the body, resulting in pathologies of the immune, renal, cardiac, and nervous systems. However, accumulating studies have reported its deleterious effects on lungs. With the better understanding of the chronic and subacute consequences of COVID-19, it is necessary to focus research efforts on finding therapies to reduce acute damage in a targeted manner while restoring physiological function and addressing the long-term consequences of this disease. Recent studies have demonstrated that mesenchymal stem cells may help to restore the lung microenvironment by preserving the alveolar epithelial cells and preventing the lung fibrosis which gives the hope that mesenchymal stem cells therapy could be the main strategy for reducing the recent pandemic. Hence, here we attempted to provide a brief overview of previously reported research work on stem cell therapy for the treatment of pulmonary fibrosis caused by SARS-COV-19.

show abstract

Macrophage‐based delivery of anti‐fibrotic proteins alleviates bleomycin‐induced pulmonary fibrosis in mice

Liu

Yang

Gao

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by chronic, progressive, and fibrotic lung injury. Although remarkable progress has been made toward understanding the pathogenesis of PF, finding more effective treatments for this fatal disease remains a challenge. In this study, we describe an innovative macrophage‐based approach to deliver anti‐fibrotic protein to the lung and inhibit PF in a mouse model of bleomycin (BLM)‐induced lung injury. We engineered macrophages to continuously secrete three types of proteins: interleukin‐10, which prevents inflammation; TGFRcFc, a soluble truncated TGF‐βR2 that blocks TGF‐β; and CD147, which induces matrix metalloproteinases (MMPs) and causes collagen degradation. Infusing these engineered macrophages into the lungs of BLM‐induced PF mouse models in an optimal pattern significantly ameliorated PF in mice. Specifically, the most effective therapeutic outcome was achieved by infusing IL‐10‐secreting macrophages on day 1, followed by TGFRcFc‐secreting macrophages on day 7 and CD147‐secreting macrophages on day 14 into the same mice after BLM treatment. Our data suggest that macrophage‐based delivery of anti‐fibrotic proteins to the lungs is a promising therapy for fibrotic lung disorders.

show abstract

Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application

Cited by 27 publications

References 70 publications

Therapeutic Effect of Astragali Radix Extract Injection Combined with Bone Marrow Mesenchymal Stem Cells in Bleomycin-Induced Pulmonary Fibrotic Rats

Therapeutic Effect of Astragali Radix Extract Injection Combined with Bone Marrow Mesenchymal Stem Cells in Bleomycin-Induced Pulmonary Fibrotic Rats

Untitled

Macrophage‐based delivery of anti‐fibrotic proteins alleviates bleomycin‐induced pulmonary fibrosis in mice

Contact Info

Product

Resources

About